Valo-C1

**Valo-C1** is an investigational oncolytic adenovirus based cancer immunotherapy developed by Valo Therapeutics. Publicly available company and pipeline materials identify it as a neoantigen or peptide coated, conditionally replicating adenoviral therapeutic vaccine designed to stimulate systemic tumor directed cytotoxic T-cell responses in cancer. Earlier descriptions refer to Valo-C1 as a genetically modified adenovirus coated with a neoantigen, while later company materials around the lead clinical asset PeptiCRAd-1 describe a related peptide coated conditionally replicating adenovirus approach built on the proprietary adenoviral backbone VALO-D102 and coated with tumor antigens such as NY-ESO-1 and MAGE-A3, with adenoviral expression of immune stimulatory molecules CD40L and OX40L. Because the exact relationship between the historical name Valo-C1 and the later clinical asset naming is not fully explicit in the sources, Valo-C1 is best described as a Valo Therapeutics oncolytic adenoviral cancer immunotherapy program in neoplasms, historically reported as preclinical and associated with induction of antitumor T-cell immunity.

Other names

neoantigen coated adenovirus vaccinePeptiCRAd